Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q4 FY26
Discovery themes featuring this stockBearish
4
Neutral
8
Bullish
2
Bearish
19
Neutral
20
Bullish
7
Bearish
15
Neutral
12
Bullish
5
Healthcare Equipment & Supplies
Medical Equipment & Supplies
1,542 Cr
Low Risk
27.2
56.6
—
3.2
735.00
431.00
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
33.50 | 2,341 Cr | 78.52 | 4.79 | 0.01 | 8.06 | 10.61 | 3.65 | ||
328.45 | 1,748 Cr | 157.44 | 2.75 | 0.00 | 2.26 | 4.09 | 0.94 | ||
661.10 | 1,542 Cr | 27.67 | 3.16 | 0.00 | 22.63 | 19.42 | 9.98 | ||
193.70 | 1,066 Cr | 37.17 | 4.38 | 0.00 | 13.74 | 14.03 | 9.76 | ||
610.50 | 888 Cr | 48.79 | 5.66 | 0.00 | 13.22 | 14.71 | 6.63 | ||
459.00 | 796 Cr | 70.57 | 4.63 | 0.00 | 5.88 | 7.65 | 5.02 | ||
368.55 | 656 Cr | 22.44 | 3.22 | 0.00 | 14.31 | 18.03 | 8.19 | ||
| Median: 7 Co. | — | 368.55 | 1,066 Cr | 48.79 | 4.38 | 0.00 | 13.22 | 14.03 | 6.63 |
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Q-Line Biotech Ltd (QLINE) is currently trading at 661.10 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Q-Line Biotech Ltd operates in the its sector sector. Review the About Company section on this page to understand its business model, revenue streams, and key products or services.
Over the past 52 weeks, Q-Line Biotech Ltd has traded between a low of ₹431.00 and a high of ₹735.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Q-Line Biotech Ltd has a market capitalization of approximately 1,542.23. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Q-Line Biotech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 27.23 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,542.23 Cr, Q-Line Biotech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Q-Line Biotech Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Q-Line Biotech Ltd is 27.23. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Regulatory/Compliance Filing
Q-Line Biotech Ltd submitted the Scrutinizer's Report for its 16th AGM held on 2026-09-30; shareholders approved adoption of standalone and consolidated audited financials for FY2025-26 and reappointment of directors.
AGM/EGM Notice
Q-Line Biotech Ltd informed the exchange of voting results and scrutinizer report for the 16th AGM held on 2026-09-30; all resolutions including adoption of standalone and consolidated financials were approved.
AGM/EGM Notice
Q-Line Biotech Ltd filed the summary of proceedings of its 16th AGM held on 2026-09-30: adoption of FY2025-26 audited financials, re-appointment of two directors, ratification of cost auditor fees; chairman noted revenue ₹341.74Cr, PAT ₹55.72Cr and Lucknow plant commissioning.
Trading Window
Q-Line Biotech Limited informed exchanges that the trading window is closed from 2026-10-01 for designated persons ahead of declaration of unaudited financial results for the half year ended 30-09-2026; window opens 48 hours after results.
